ClinicalTrials.gg
RecruitingNCT07616453TAYLOR-002Updated Jun 1, 2026

Efficacy and Safety of Culmerciclib Plus Aromatase Inhibitors in a Response-Adapted Neoadjuvant Strategy for Highly Proliferative ER-Positive/HER2-Negative Breast Cancer

A Phase 2 interventional study of Culmerciclib and Aromatase Inhibitors in HR+/HER2- Early Breast Cancer, sponsored by Second Affiliated Hospital, School of Medicine, Zhejiang University. Recruiting at 1 site in China. Open to female participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-06-01.

Sponsored by Second Affiliated Hospital, School of Medicine, Zhejiang University · Phase 2, Interventional, and Treatment

How we know · 6 judgments

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
45
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 15 studies testing culmerciclib in Breast Neoplasms — 8 open to participants now, 11 under way, 2 of them phase 3. culmerciclib · Breast Neoplasms.

Planned enrollment
7th of 15
45 · median 40
Started
2026
with 6 others
Phase 2
9 of 15
7 open now
Primary completion
2028-05
later than 6 of 10 live
Registered
9th of 15
by date
Lead sponsor
1 of 15
Second Affiliated Hospital, School of Medicine, Zhejiang University

Among the 15 studies testing culmerciclib in Breast Neoplasms, this one is the 7th largest by planned enrollment, is one of 7 that started in 2026, is one of 9 in phase 2, reaches primary completion later than 6 of the 10 other live ones, and was the 9th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

8 of the 15 studies testing culmerciclib in Breast Neoplasms are open now, in 1 country. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Where they have run

About culmerciclib

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years to 75 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies testing culmerciclib in Breast Neoplasms, or all of them as a file.
02

Study summary

This prospective, response-adapted phase II study evaluates the efficacy and safety of neoadjuvant culmerciclib in combination with aromatase inhibitors in patients with highly proliferative ER-positive/HER2-negative breast cancer. All patients initially receive induction treatment with culmerciclib plus endocrine therapy, followed by on-treatment assessment of biological and clinical response. Patients demonstrating an adequate response continue the same regimen, whereas those with a suboptimal response are transitioned to alternative treatment strategies prior to surgery. This adaptive approach aims to optimize treatment selection, improve therapeutic efficacy, and avoid unnecessary exposure to ineffective therapy.

Read the detailed description

This is a prospective, response-adapted, phase II study designed to evaluate an individualized neoadjuvant treatment strategy based on culmerciclib in combination with aromatase inhibitors in patients with highly proliferative ER-positive/HER2-negative early breast cancer. The study incorporates an adaptive treatment algorithm guided by on-treatment assessment of tumor response, with the aim of optimizing therapeutic efficacy while minimizing unnecessary treatment exposure.

All eligible patients initially receive neoadjuvant treatment with culmerciclib plus endocrine therapy according to the study protocol. Following completion of a predefined initial treatment phase, tumor response is assessed using biological and clinical evaluation methods.

Patients who achieve an adequate response continue the same neoadjuvant regimen to complete the planned course of therapy. In contrast, patients demonstrating a suboptimal response are transitioned to alternative treatment strategies prior to surgery. Subsequent treatment selection and management are conducted according to protocol-defined principles and investigator assessment.

This response-adapted strategy is intended to address the clinical heterogeneity of endocrine sensitivity in ER-positive/HER2-negative breast cancer. By tailoring treatment intensity according to early response, the study seeks to maximize therapeutic benefit in responsive patients while facilitating timely treatment modification for those less likely to benefit from the initial regimen.

Primary and secondary objectives include evaluation of clinical efficacy, safety and tolerability of the response-adapted neoadjuvant strategy, and the feasibility of treatment modification based on early response assessment. Exploratory analyses will investigate potential biomarkers associated with treatment response and resistance, with the goal of informing future individualized treatment approaches.

03

Conditions studied

  • HR+/HER2- Early Breast Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria Female patients aged ≥18 and ≤75 years. confirmed estrogen receptor (ER)-positive (≥10%) and -negative breast cancer, according to the 2018 ASCO/CAP guidelines. HER2-negative status is defined as immunohistochemistry (IHC) 0 or 1+, or IHC 2+ with negative in situ hybridization (ISH) (ISH ratio \<2.0), as confirmed by a certified pathology laboratory.

Ki-67 ≥20% assessed on core needle samples. Newly diagnosed, treatment-naïve patients with stage I-IIIA disease according to the AJCC 8th edition.

(ECOG) performance status of 0-1.

Adequate bone marrow function:

  1. ≥1.5 × 10⁹/L (without growth factor support within 14 days);
  2. count ≥100 × 10⁹/L (without transfusion or supportive therapy within 7 days);
  3. ≥100 g/L (without transfusion within 7 days).

Adequate hepatic and renal function:

  1. Total ≤1 × (ULN);
  2. (ALT) and aspartate aminotransferase (AST) ≤3 × ULN (≤5 × ULN in patients with liver );
  3. Blood urea nitrogen and serum creatinine ≤1.5 × ULN, and ≥50 mL/min (calculated using the Cockcroft-Gault formula).

(LVEF) ≥50% as assessed by echocardiography. ≤480 ms on 12-lead (ECG). Ability and willingness to undergo tumor biopsy. Provision of written . Exclusion Criteria Prior receipt of any anticancer therapy, including chemotherapy, radiotherapy, targeted therapy, or endocrine therapy.

Concurrent treatment with other anticancer agents. Bilateral breast cancer, inflammatory breast cancer, or occult breast cancer. Stage IV breast cancer. Breast cancer not confirmed by histopathology. History of other within the past 5 years, except for adequately treated carcinoma in situ of the cervix.

Severe dysfunction of major organs, including heart, liver, or kidneys. Conditions affecting oral drug administration or absorption, including inability to swallow, chronic diarrhea, or intestinal obstruction.

Participation in another interventional clinical trial within 4 weeks prior to enrollment.

Known to any component of the study drugs; history of immunodeficiency, including infection, active or C infection, other acquired or congenital immunodeficiency disorders, or history of organ transplantation.

History of significant cardiovascular disease, including but not limited to arrhythmias requiring treatment, myocardial infarction, heart failure, or any other cardiac condition deemed unsuitable by the investigator.

Pregnant or breastfeeding women; women of with a positive pregnancy test at baseline, or unwilling to use effective during the study period.

Any serious concomitant disease that, in the investigator's judgment, may compromise patient safety or compliance with the study, including but not limited to uncontrolled hypertension, severe diabetes, or active infection.

History of neurological or psychiatric disorders, including epilepsy or dementia.

Any other condition that, in the investigator's opinion, makes the patient unsuitable for participation in the study.

Terms in these criteria, in plain language(23)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
45 participants (estimated)

Study arms

  • Experimental
    Culmerciclib plus AI

    Drug: Culmerciclib · Drug: Aromatase Inhibitors

Interventions

This study also gives AnastrozoleStudies of AnastrozoleAnastrozole pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. Complete cell cycle arrest (CCCA)

    Ki67≤2.7%

    Time frame: 4 weeks

Secondary outcomes

  1. the proportion of patients with Residual Cancer Burden (RCB) class 0-1

    Time frame: 24 weeks

  2. Total Pathological Complete Response (tpCR) Rate

    Time frame: 24 weeks

  3. Objective Response Rate (ORR)

    Time frame: 24 weeks

  4. Event-Free Survival (EFS)

    EFS is defined as the time from randomization to any of the following events: precludes surgery, local or distant recurrence, second primary malignancy, or death due to any cause.

    Time frame: Approximately five years

  5. Adverse Event (AE)

    An AE is defined as any untoward medical occurrence in a study participant administered a medicinal product, temporally associated with study intervention, without presumption of causality.

    Time frame: Approximately three years

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for May 2026; primary completion for May 2028, 23 months later.

Of 1,070 non-industry phase 2 interventional studies under Breast Neoplasms, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 89. This study's planned 23 months is below that.

Counting every sponsor, half of 1,302 studies reached it within 51 months; a quarter within 30 and three quarters within 83.

How these figures are worked out, and which studies are left out of them.

Registered
May 24, 2026
First posted
Jun 1, 2026
StartEst.
May 6, 2026
Primary completionEst.
May 5, 2028
CompletionEst.
May 5, 2033
Last update
Jun 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07616453
Responsible party
Sponsor
First posted
Jun 1, 2026
Start date
May 6, 2026 (estimated)
Primary completion
May 5, 2028 (estimated)
Completion
May 5, 2033 (estimated)
Last update
Jun 1, 2026

Study contacts

Yunxiang Zhou
Contact
yxzhou@zju.edu.cn
15868131018
Yiding Chen
principal investigator · Second Affiliated Hospital, School of Medicine, Zhejiang University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Culmerciclib · Aromatase inhibitors

Start the discussion